Antiadenovirus drug discovery: potential targets and evaluation methodologies

Drug Discovery Today

Volumn 20, Issue 10, 2015, Pages 1235-1242

  Martínez Aguado, Pablo ^a   Serna Gallego, Ana ^a   Marrugal Lorenzo, José A ^a   Gómez Marín, Isabel ^a   Sánchez Céspedes, Javier ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BRINCIDOFOVIR; CIDOFOVIR; EPIGALLOCATECHIN GALLATE; ERITORAN; GANCICLOVIR; LEPTOMYCIN B; NICLOSAMIDE; RATJADONE; RIBAVIRIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; DNA DAMAGE; DNA REPLICATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EVALUATION STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN ADENOVIRUS C; HUMAN CYTOMEGALOVIRUS; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MOLECULE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS STRAIN; ADENOVIRUS INFECTIONS, HUMAN; ANIMAL; DRUG DEVELOPMENT; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; MOLECULARLY TARGETED THERAPY; VIROLOGY;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; IMMUNOCOMPROMISED HOST; MOLECULAR TARGETED THERAPY;

EID: 84944441345     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.07.007     Document Type: Review

References (113)

1. R.R. Razonable, and A.J. Eid Viral infections in transplant recipients Minerva Med. 100 2009 479 501
2. S. Matthes-Martin, and et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011) Transpl. Infect. Dis. 14 2012 555 563
3. L. Lenaerts, and et al. Clinical features and treatment of adenovirus infections Rev. Med. Virol. 18 2008 357 374
4. S. Matthes-Martin, and et al. Diagnosis and treatment of adenovirus infection in immunocompromised patients Expert Rev. Anti. Infect. Ther. 11 2013 1017 1028
5. T. Lion Adenovirus infections in immunocompetent and immunocompromised patients Clin. Microbiol. Rev. 27 2014 441 462
6. F. Morfin, and et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent Antiviral Ther. 10 2005 225 229
7. L. Naesens, and et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues Antimicrob. Agents Chemother. 49 2005 1010 1016
8. L. Lenaerts, and L. Naesens Antiviral therapy for adenovirus infections Antiviral Res. 71 2006 172 180
9. S. Safrin, and et al. Cidofovir. Review of current and potential clinical uses Adv. Exp. Med. Biol. 458 1999 111 120
10. J. Lujan-Zilbermann Infections in hematopoietic stem cell transplant recipients S.S. Long, L.K. Pickering, C.G. Prober, Principles & Practice of Pediatric Infectious Diseases 2008 Churchill Livingstone 562 566
11. J. Sanchez-Cespedes, and et al. Inhibition of adenovirus replication by a trisubstituted piperazin-2-one derivative Antiviral Res. 108 2014 65 73
12. Marketing authorisation for Vistide withdrawn Pharm. J. 293 2014
13. T. Lion, and et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation Leukemia 24 2010 706 714
14. C.A. Lindemans, and et al. How I treat adenovirus in hematopoietic stem cell transplant recipients Blood 116 2010 5476 5485
15. U. Yusuf, and et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients Transplantation 81 2006 1398 1404
16. N. Symeonidis, and et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir Transpl. Infect. Dis. 9 2007 108 113
17. V.A. Bhadri, and et al. Safety and tolerability of cidofovir in high-risk pediatric patients Transpl. Infect. Dis. 11 2009 373 379
18. K.Y. Hostetler Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art Antiviral Res. 82 2009 A84 A98
19. K. Toth, and et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model Proc. Natl. Acad. Sci. U. S. A. 105 2008 7293 7297
20. W. Painter, and et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses Antimicrob. Agents Chemother. 56 2012 2726 2734
21. J.D. Graci, and C.E. Cameron Mechanisms of action of ribavirin against distinct viruses Rev. Med. Virol. 16 2006 37 48
22. F. Morfin, and et al. Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone Antivir. Ther. 14 2009 55 61
23. P. Bordigoni, and et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation Clin. Infect. Dis. 32 2001 1290 1297
24. F.E. Chen, and et al. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir Bone Marrow Transplant. 20 1997 997 999
25. K. Kurosaki, and et al. Therapeutic basis of vidarabine on adenovirus-induced haemorrhagic cystitis Antiviral Chem. Chemother. 15 2004 281 285
26. B. Bruno, and et al. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival Biol. Blood Marrow Transplant. 9 2003 341 352
27. R. Vij, and et al. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation Bone Marrow Transplant. 32 2003 703 707
28. B. Ying, and et al. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters Antimicrob. Agents Chemother. 58 2014 7171 7181
29. K. Toth, and et al. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters Viruses 7 2015 1409 1428
30. W.S. Wold, and K. Toth Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds Adv. Cancer Res. 115 2012 69 92
31. S. Chakrabarti, and et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery Blood 100 2002 1619 1627
32. P. Moss, and A. Rickinson Cellular immunotherapy for viral infection after HSC transplantation Nat. Rev. Immunol. 5 2005 9 20
33. A.M. Leen, and et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy J. Virol. 82 2008 546 554
34. A.W. Sylwester, and et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects J. Exp. Med. 202 2005 673 685
35. A.D. Hislop, and et al. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection J. Exp. Med. 195 2002 893 905
36. U. Gerdemann, and et al. Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host Mol. Ther. 17 2009 1616 1625
37. P.J. Hanley, and et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation Cytotherapy 13 2011 976 986
38. M.L. Zandvliet, and et al. Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection Haematologica 95 2010 1943 1951
39. T. Feuchtinger, and et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation Br. J. Haematol. 134 2006 64 76
40. L.M. Haveman, and et al. Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen presenting cells Clin. Immunol. 146 2013 228 239
41. U. Gerdemann, and et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections Mol. Ther. 20 2012 1622 1632
42. U. Gerdemann, and et al. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant J. Vis. Exp. 51 2011 e2736 10.3791/2736
43. S. Tischer, and et al. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells J. Transl. Med. 12 2014 336
44. J.J. Melenhorst, and et al. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells Mol. Ther. 23 2015 179 183
45. U. Gerdemann, and et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant Mol. Ther. 21 2013 2113 2121
46. T. Haque, and et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial Blood 110 2007 1123 1131
47. G.M. Wilkie, and et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases J. Immunother. 27 2004 309 316
48. W.J. McGrath, and et al. First generation inhibitors of the adenovirus proteinase FEBS Lett. 587 2013 2332 2339
49. H. Kaneko, and et al. Antiviral activity of NMSO3 against adenovirus in vitro Antiviral Res. 52 2001 281 288
50. R. Gainotti, and et al. Real time PCR for rapid determination of susceptibility of adenovirus to antiviral drugs J. Virol. Methods 164 2010 30 34
51. J.G. Smith, and G.R. Nemerow Mechanism of adenovirus neutralization by human alpha-defensins Cell Host Microbe 3 2008 11 19
52. C.L. Moyer, and et al. Functional genetic and biophysical analyses of membrane disruption by human adenovirus J. Virol. 85 2011 2631 2641
53. I.H. Wang, and et al. Tracking viral genomes in host cells at single-molecule resolution Cell Host Microbe 14 2013 468 480
54. M. Suomalainen, and et al. A direct and versatile assay measuring membrane penetration of adenovirus in single cells J. Virol. 87 2013 12367 12379
55. N. Imelli, and et al. Genetic reconstitution of the human adenovirus type 2 temperature-sensitive 1 mutant defective in endosomal escape Virol. J. 6 2009 174
56. A. Yakimovich, and et al. Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model J. Virol. 86 2012 10123 10137
57. K. Solly, and et al. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays Assay Drug Dev. Technol. 2 2004 363 372
58. D. Puntener, and et al. Stepwise loss of fluorescent core protein V from human adenovirus during entry into cells J. Virol. 85 2011 481 496
59. F.J. Prado-Prado, and et al. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds Bioorg. Med. Chem. 16 2008 5871 5880
60. I. Diaconu, and et al. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir J. Gene Med. 12 2010 435 445
61. A.E. Tollefson, and et al. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model Antiviral Res. 112 2014 38 46
62. L. Lenaerts, and et al. Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections Antimicrob. Agents Chemother. 49 2005 4689 4699
63. C. Jogler, and et al. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species J. Virol. 80 2006 3549 3558
64. V.V. Ternovoi, and et al. Productive replication of human adenovirus type 5 in canine cells J. Virol. 79 2005 1308 1311
65. P.R. Kinchington, and et al. Prospects for adenovirus antivirals J. Antimicrob. Chemother. 55 2005 424 429
66. K. Toth, and et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses Hum. Gene Ther. 16 2005 139 146
67. G.A. Prince, and et al. Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus) J. Virol. 67 1993 101 111
68. G.R. Nemerow, and et al. Insights into adenovirus host cell interactions from structural studies Virology 384 2009 380 388
69. A. Gaggar, and et al. CD46 is a cellular receptor for group B adenoviruses Nat. Med. 9 2003 1408 1412
70. J.M. Bergelson, and et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 Science 275 1997 1320 1323
71. H. Wang, and et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14 Nat. Med. 17 2011 96 104
72. H.V. Trinh, and et al. Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection J. Virol. 86 2012 1623 1637
73. J.G. Smith, and et al. Adenovirus Curr. Top. Microbiol. Immunol. 343 2010 195 224
74. C. Lyle, and F. McCormick Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells Virol. J. 7 2010 148
75. C.C. Colpitts, and L.M. Schang A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans J. Virol. 88 2014 7806 7817
76. M.C. Dechecchi, and et al. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions Virology 268 2000 382 390
77. E. Uchio, and et al. Antiadenoviral effect of the alpha 5 beta 1 integrin receptor ligand, GRGDSP peptide, in serotypes that cause acute keratoconjunctivitis Ophthalmologica 221 2007 326 330
78. A. Pietrantoni, and et al. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides Antimicrob. Agents Chemother. 47 2003 2688 2691
79. P.J. Hippenmeyer, and et al. Adenovirus inhibition by peptidomimetic integrin antagonists Antiviral Res. 55 2002 169 178
80. U.F. Greber, and et al. Stepwise dismantling of adenovirus 2 during entry into cells Cell 75 1993 477 486
81. M. Suomalainen, and et al. Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus J. Cell Biol. 144 1999 657 672
82. N.D. Myers, and et al. Directed evolution of mutator adenoviruses resistant to antibody neutralization J. Virol. 87 2013 6047 6050
83. J.G. Smith, and et al. Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport J. Virol. 82 2008 6492 6500
84. S. Strunze, and et al. Nuclear targeting of adenovirus type 2 requires CRM1-mediated nuclear export Mol. Biol. Cell 16 2005 2999 3009
85. S. Strunze, and et al. Kinesin-1-mediated capsid disassembly and disruption of the nuclear pore complex promote virus infection Cell Host Microbe 10 2011 210 223
86. W.A. McEwan, and et al. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21 Nat. Immunol. 14 2013 327 336
87. H. Zhao, and et al. Strategic attack on host cell gene expression during adenovirus infection J. Virol. 77 2003 11006 11015
88. D. Kneidinger, and et al. Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery Antiviral Res. 94 2012 195 207
89. U. Pettersson, and R.J. Roberts Adenovirus gene expression and replication: a historical review DNA Tumor Viruses: Control of Gene Expression and Replication 1986 Cold Spring Harbor Laboratory 37 57
90. J.L. Stevens, and et al. Transcription control by E1 A and MAP kinase pathway via Sur2 mediator subunit Science 296 2002 755 758
91. G.A. Horwitz, and et al. Adenovirus small e1a alters global patterns of histone modification Science 321 2008 1084 1085
92. R. Ferrari, and et al. Adenovirus small E1A employs the lysine acetylases p300/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection Cell Host Microbe 16 2014 663 676
93. A. Eckstein, and et al. Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions Antiviral Res. 88 2010 86 94
94. Y.S. Chung, and et al. Silencing E1A mRNA by RNA interference inhibits adenovirus replication Arch. Virol. 152 2007 1305 1314
95. M.G. Andersson, and et al. Suppression of RNA interference by adenovirus virus-associated RNA J. Virol. 79 2005 9556 9565
96. J.M. Weber Adenain, the adenovirus endoprotease Acta Microbiol. Immunol. Hung. 50 2003 95 101 (review)
97. W.F. Mangel, and C. San Martin Structure, function and dynamics in adenovirus maturation Viruses 6 2014 4536 4570
98. P. Grosche, and et al. Structure-based design and optimization of potent inhibitors of the adenoviral protease Bioorg. Med. Chem. Lett. 25 2015 438 443
99. A. Mac Sweeney, and et al. Discovery and structure-based optimization of adenain inhibitors ACS Med. Chem. Lett. 5 2014 937 941
100. A. Jurgeit, and et al. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects PLoS Pathog. 8 2012 e1002976
101. L. Perez, and L. Carrasco Involvement of the vacuolar H(+)-ATPase in animal virus entry J. Gen. Virol. 75 1994 2595 2606
102. M.C. Patel, and et al. Novel drugs targeting Toll-like receptors for antiviral therapy Future Virol. 9 2014 811 829
103. R. Hendrickx, and et al. Innate immunity to adenovirus Hum. Gene Ther. 25 2014 265 284
104. M. Iacobelli-Martinez, and G.R. Nemerow Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses J. Virol. 81 2007 1305 1312
105. D.M. Appledorn, and et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo J. Immunol. 181 2008 2134 2144
106. K. Doronin, and et al. Coagulation factor X activates innate immunity to human species C adenovirus Science 338 2012 795 798
107. K.A. Shirey, and et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection Nature 497 2013 498 502
108. S. Schreiner, and et al. SPOC1-mediated antiviral host cell response is antagonized early in human adenovirus type 5 infection PLoS Pathog. 9 2013 e1003775
109. J. Berscheminski, and et al. Sp100 isoform-specific regulation of human adenovirus 5 gene expression J. Virol. 88 2014 6076 6092
110. Y.E. Kim, and et al. Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression J. Virol. 85 2011 11928 11937
111. F. Full, and et al. Herpesvirus saimiri antagonizes nuclear domain 10-instituted intrinsic immunity via an ORF3-mediated selective degradation of cellular protein Sp100 J. Virol. 86 2012 3541 3553
112. M. Malumbres, and M. Barbacid Cell cycle, CDKs and cancer: a changing paradigm Na. Rev. Cancer 9 2009 153 166
113. M. Yamamoto, and et al. CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses J. Clin. Invest. 124 2014 3479 3488